Polivy Approval and Core Survival Data
Polivy (polatuzumab vedotin), from Genentech, is approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab (BR). In the phase 2 GO29365 trial, Polivy plus BR improved median overall survival (OS) to 12.4 months versus 4.7 months with BR alone (hazard ratio [HR] 0.42, p<0.0001). Progression-free survival (PFS) was 7.6 months versus 2.0 months (HR 0.36).[1][2]
How Polivy Works for Survival Gains
Polivy is an antibody-drug conjugate targeting CD79b on B-cells, delivering monomethyl auristatin E to kill cancer cells. This added cytotoxicity to BR chemotherapy boosts response rates (complete response 40% vs 18%), driving the OS benefit in patients unfit for transplant or CAR-T after prior rituximab therapy.[1][3]
Survival in Frontline DLBCL Setting
In the phase 3 POLARIX trial for first-line DLBCL, Polivy plus R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) extended PFS to a median not reached at 28 months (vs 20 months for R-CHOP; HR 0.73, p=0.001). OS data remain immature, with no significant difference at 3 years (94% vs 94%).[2][4]
Who Sees the Biggest Survival Boost
Third-line patients with high-risk features (e.g., double-hit lymphoma, elevated LDH) gained most from Polivy+BR, with OS HR 0.49 in subgroups. Benefits held across age groups over 65, but frontline use shows PFS edge without OS maturity yet.[1][5]
Risks and Tradeoffs for Survival
Common adverse events include neutropenia (42%), thrombocytopenia (27%), and neuropathy (40%), leading to 19% discontinuations. These offset gains in frail patients, where infection risk rises.[2][3] No DrugPatentWatch data on survival; patents cover formulation until 2031-2033.[6]
[1]: FDA Label for Polivy
[2]: NEJM: GO29365 Trial
[3]: Sehn et al., Lancet Oncology (2020)
[4]: Tilly et al., NEJM (2022)
[5]: Genentech POLARIX Update (ASCO 2023)
[6]: DrugPatentWatch.com - Polivy Patents